Lupus

Akhil Sood MD AkhilSoodMD
10 months 3 weeks ago
Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if there are less-invasive methods? In this article, I highlight key abstracts exploring innovative approaches.
https://t.co/ZInKmVS2Gn
@RheumNow #ACR24

David Liew drdavidliew
10 months 3 weeks ago
Can you build systems that stop that ANA neg ENA pos anxiety? Plus $$?
Lehigh Valley, Allentown, PA:
lab would run ENA+dsDNA automatically, but only when ANA >1:80
(i.e. leave the ENA order to the lab)
first voluntary, then compulsory
it's possible!
#ACR24 ABST1931 @RheumNow https://t.co/UQjWwve7DV


David Liew drdavidliew
10 months 3 weeks ago
ANA neg, but ENA pos
should we care about that result?
PPV 5.5% here
(similar to 6% prev @EricFMorand: https://t.co/Hyaued3rw2)
and how many really needed the serology? Anxiety?
Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️
#ACR24 ABST1930 @RheumNow https://t.co/rE7RmgOGey


Brian Jaros, MD Dr_Brian_MD
10 months 3 weeks ago
VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ


Brian Jaros, MD Dr_Brian_MD
10 months 3 weeks ago
What a result!!!
Crowed split 49% against and 51% for MCTD as a unique disease entity
Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group
Fantastic session from all the presenters
@RheumNow #ACR24 https://t.co/GgTVQ1VNWP


Brian Jaros, MD Dr_Brian_MD
10 months 3 weeks ago
The anti-MCTD group strikes back
Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD
Majority of patients, despite potential overlap, treated for other primary rheum dz
@RheumNow #ACR24 https://t.co/vkQ6UPs34y


Mike Putman EBRheum
10 months 3 weeks ago
Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato
Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH
Encouraging data for JAKs in this disease; need proper trials
#ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip


Brian Jaros, MD Dr_Brian_MD
10 months 3 weeks ago
On now: The Great Debate - is MCTD a distinct clinical entity?
@DrLisaCS reviews the history of MCTD classification criteria and its evolution
Kasukawa criteria may be most sensitive in one cohort
@RheumNow #ACR24 https://t.co/rDHafZVL1I


Akhil Sood MD AkhilSoodMD
10 months 3 weeks ago
Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II.
@RheumNow #ACR24 https://t.co/kufd2zl9yc


Akhil Sood MD AkhilSoodMD
10 months 3 weeks ago
Is there a less invasive approach to evaluate lupus nephritis?
Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways.
@RheumNow #ACR24

Akhil Sood MD AkhilSoodMD
10 months 3 weeks ago
Will my patient with lupus nephritis respond well to induction therapy?
Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V)
@RheumNow #ACR24 https://t.co/JBldrrwUhN


Bella Mehta bella_mehta
10 months 3 weeks ago
Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE
Belimumab ~ 600% increase!!
@RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF
